Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – Research analysts at HC Wainwright upped their FY2029 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a report issued on Tuesday, December 3rd. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of $1.19 per share for the year, up from their prior forecast of $1.16. HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.09) per share.
Other equities analysts have also issued research reports about the stock. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Wednesday, November 27th. Sanford C. Bernstein reduced their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. Piper Sandler decreased their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. Finally, B. Riley reiterated a “buy” rating and set a $55.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $42.70.
Arrowhead Pharmaceuticals Stock Down 3.5 %
Shares of Arrowhead Pharmaceuticals stock opened at $22.30 on Thursday. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of -4.44 and a beta of 0.91. The stock has a 50-day simple moving average of $20.53 and a 200-day simple moving average of $23.23. Arrowhead Pharmaceuticals has a 52-week low of $17.05 and a 52-week high of $39.83. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 3.9% during the 2nd quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after purchasing an additional 333,333 shares during the period. State Street Corp grew its position in Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after buying an additional 516,569 shares in the last quarter. Geode Capital Management LLC increased its stake in Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock valued at $57,426,000 after acquiring an additional 26,171 shares during the period. Bank of New York Mellon Corp raised its holdings in Arrowhead Pharmaceuticals by 2.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,085,069 shares of the biotechnology company’s stock valued at $28,201,000 after acquiring an additional 30,086 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 1.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock worth $19,504,000 after acquiring an additional 12,574 shares during the period. 62.61% of the stock is owned by institutional investors.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Featured Articles
- Five stocks we like better than Arrowhead Pharmaceuticals
- 3 Ways To Invest In Coffee, Other Than Drinking It
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- Stock Market Upgrades: What Are They?
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- How to buy stock: A step-by-step guide for beginners
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.